8-K
filed June 21, 2023, 7:59 PM ET
ticker ANIK
CIK 0000898437
leadership
confidence high
sentiment neutral
materiality 0.35
Anika appoints Anne Nunes as SVP, COO; shareholders approve 435K-share plan increase
Anika Therapeutics, Inc.
- Anne Nunes appointed SVP, Chief Operations Officer effective June 19, 2023; base salary $440,000, target bonus 45%.
- Stockholders approved amendment increasing 2017 Plan share reserve by 435,000 to 5,285,000 shares.
- Gary Fischetti, John Henneman, and Susan Vogt elected Class III directors until 2026 annual meeting.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 1.0
Anne Nunes was appointed as Senior Vice President, Chief Operations Officer at Anika Therapeutics, Inc..
- Action
- appointed
- Role
- Senior Vice President, Chief Operations Officer
Exact text from the filing
On June 14, 2023, the Board appointed Anne Nunes, age 54, as the Company’s Senior Vice President, Chief Operations Officer, effective as of June 19, 2023.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Anika Therapeutics, Inc. shareholders approved Non-binding advisory vote to approve compensation of named executive officers at the 2023-06-14 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-06-14
Exact text from the filing
Stockholders voted as follows with respect to this proposal: For Against Abstain Broker Non-Votes 11,873,054 227,519 51,162 1,168,309
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Anika Therapeutics, Inc. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-14 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-14
Exact text from the filing
Stockholders voted as follows with respect to this ratification proposal: For Against Abstain Broker Non-Votes 13,279,828 27,825 12,391 0
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Anika Therapeutics, Inc. shareholders approved Amendment to the 2017 Amended and Restated Stock Incentive Plan to increase authorized shares by 435,000 at the 2023-06-14 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-06-14
Exact text from the filing
Stockholders voted as follows with respect to this proposal: For Against Abstain Broker Non-Votes 9,807,584 2,331,160 12,991 1,168,309
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Anika Therapeutics, Inc. shareholders approved Non-binding advisory vote on frequency of future advisory votes on executive compensation at the 2023-06-14 meeting.
- Proposal
- say on pay frequency
- Outcome
- passed
- Meeting
- 2023-06-14
Exact text from the filing
Stockholders voted, on a non-binding, advisory basis, as follows with respect to the frequency of future advisory votes on compensation paid to the Company's named executive officers: 1 Year 2 Years 3 Years Abstain 11,078,317 3,067 1,038,679 31,672
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Anika Therapeutics, Inc. shareholders approved Election of three Class III directors at the 2023-06-14 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-14
Exact text from the filing
Stockholders voted as follows with respect to election of each of the director nominees identified in the Proxy Statement: Nominee For Against Abstain Broker Non-Votes Gary P. Fischetti 12,032,739 106,519 12,477 1,168,309 John B. Henneman, III 11,054,795 1,079,499 17,441 1,168,309 Susan L. N. Vogt 11,721,294 417,401 13,040 1,168,309
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.